Biodexa Pharmaceuticals Plc

NasdaqCM:BDRX Voorraadrapport

Marktkapitalisatie: US$3.4m

Biodexa Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

Biodexa Pharmaceuticals' CEO is Stephen Stamp, appointed in Sep 2019, has a tenure of 5.17 years. total yearly compensation is £252.00K, comprised of 99.2% salary and 0.8% bonuses, including company stock and options. directly owns 0% of the company’s shares, worth $5.84. The average tenure of the management team and the board of directors is 2.4 years and 7.5 years respectively.

Belangrijke informatie

Stephen Stamp

Algemeen directeur

UK£252.0k

Totale compensatie

Percentage CEO-salaris99.2%
Dienstverband CEO5.2yrs
Eigendom CEO0.0002%
Management gemiddelde ambtstermijn2.4yrs
Gemiddelde ambtstermijn bestuur7.5yrs

Recente managementupdates

Recent updates

Midatech Pharma regains compliance with Nasdaq's minimum bid price requirement

Oct 18

Midatech Pharma reports 1H results

Sep 14

Midatech surges on the promise of drug delivery system

Jun 17

Analyse CEO-vergoeding

Hoe is Stephen Stamp's beloning veranderd ten opzichte van Biodexa Pharmaceuticals's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-UK£7m

Mar 31 2024n/an/a

-UK£7m

Dec 31 2023UK£252kUK£250k

-UK£7m

Sep 30 2023n/an/a

-UK£8m

Jun 30 2023n/an/a

-UK£8m

Mar 31 2023n/an/a

-UK£8m

Dec 31 2022UK£238kUK£236k

-UK£8m

Sep 30 2022n/an/a

-UK£7m

Jun 30 2022n/an/a

-UK£5m

Mar 31 2022n/an/a

-UK£5m

Dec 31 2021UK£329kUK£187k

-UK£5m

Sep 30 2021n/an/a

-UK£7m

Jun 30 2021n/an/a

-UK£8m

Mar 31 2021n/an/a

-UK£15m

Dec 31 2020UK£193kUK£175k

-UK£22m

Jun 30 2020n/an/a

-UK£22m

Mar 31 2020n/an/a

-UK£16m

Dec 31 2019UK£207kUK£50k

-UK£9m

Compensatie versus markt: Stephen's total compensation ($USD325.61K) is below average for companies of similar size in the US market ($USD655.65K).

Compensatie versus inkomsten: Stephen's compensation has increased whilst the company is unprofitable.

CEO

Stephen Stamp (62 yo)

5.2yrs

Tenure

UK£252,003

Compensatie

Mr. Stephen A. Stamp serves as Chief Financial Officer and Director of Biodexa Pharmaceuticals Plc (formerly known as Midatech Pharma plc) since September 9, 2019. He serves as Chief Executive Officer at B...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Stephen Stamp
CEO, CFO5.2yrsUK£252.00k0.00017%
$ 5.8
Daniel Palmer
Vice President of Technology3.8yrsgeen gegevensgeen gegevens
Nicola Tuckwell
VP & Head of Clinical Operationsless than a yeargeen gegevensgeen gegevens
Steve Ellul
Chief Business Officerless than a yeargeen gegevensgeen gegevens
Fiona Sharp
Group Financial Controllerno datageen gegevensgeen gegevens

2.4yrs

Gemiddelde duur

Ervaren management: BDRX's management team is considered experienced (2.4 years average tenure).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Stephen Stamp
CEO, CFO5.2yrsUK£252.00k0.00017%
$ 5.8
Simon Turton
Senior Independent Non-Executive Director9.9yrsUK£31.92k0.00017%
$ 5.8
Stephen Parker
Independent Non-Executive Chairman2.4yrsUK£82.00kgeen gegevens
Daniel McCurdy
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Sijmen de Vries
Independent Non-Executive Director20.1yrsUK£31.92k0.00017%
$ 5.8
Michael Natan
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Francesco Stellaci
Chairman of Scientific Advisory Boardno datageen gegevensgeen gegevens
David Male
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Lorraine O'Driscoll
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Soledad Penades
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Jean-Christophe Roux
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Silke Krol
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens

7.5yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: BDRX's board of directors are considered experienced (7.5 years average tenure).